

POSTER SESSION II - Tuesday 27 September 2022

ABSTRACT	TITLE	PRESENTER
TRANSLATIONAL: COVID-19 - Vaccines (focus: vaccines in use, late stage development and pan-coronavirus vaccines)		
AOXI0026	Booster Dose of mRNA Vaccine Increased Protection Against SARS-CoV-2 Infection During Period of Omicron Circulation in A Rural Wisconsin Cohort	Jennifer King
AOXI0081	Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: a prospective cohort study in Japan	Tomoka Matsuura
AOXI0182	SARS-CoV-2 vaccines induce equivalent or greater antibody responses in adolescents compared with adults	Carolyn Cohen
AOXI0184	Antibody avidity and neutralizing response against SARS-CoV-2 Omicron variant after infection or vaccination	Serena Marchi
AOXI0191	Lowered immune response of SARS-CoV-2 vaccine among elderly residents of geriatric long-term care facilities improved by the booster dose	Satoko Ohfuji
AOXI0211	Analysis of initial cellular immune responses to breakthrough SARS-CoV-2 infection following primary series AZD1222 (ChAdOx1 nCoV-19) vaccination	Phil Swanson
AOXI0246	An intranasal influenza virus-vectored vaccine protects against SARS-CoV-2 variants in mice and Syrian hamsters	Shaofeng Deng
AOXI0251	Comparison of the evolution of SARS-COV 2 variant distribution and seroprevalence estimates during the Sanofi Adjuvanted Recombinant Protein Vaccine efficacy trial: an epidemiology perspective.	Clotilde El Guerche Seblain
AOXI0311	HUMORAL IMMUNE RESPONSE AGAINST SARS-CoV-2 VARIANTS AFTER TWO DOSES OF mRNA VACCINE IN AN ITALIAN CORRECTIONAL FACILITY	Claudia Trombetta
AOXI0324	Comparison of Omicron BA.1-specific T cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong	Ka Pun Mok (Chris)
AOXI0332	Recombinant NDV-vectored SARS-CoV-2 Spike gene Live vaccine protect hACE-2 mouse from Lethal infection of the SARS-CoV-2	Deok Hwan kim
AOXI0341	Different kinetics of seasonal and pandemic human coronavirus reactive antibodies after repeated vaccination in adults and the elderly	Fan Zhou
AOXI0359	Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens	Wanitchaya Kittikraisak
AOXI0379	COVID-19 vaccine booster recovered the antibody titers acquired after the primary vaccination scheme	Raquel Guiomar
AOXI0395	COVID-19 Post-vaccination in Healthcare Workers and Vaccine Effectiveness, Brazil, 2021	Caio Fernandes
AOXI0405	Duration of protection against SARS-CoV2: implications for development of new candidate vaccines and booster vaccination recommendations	Cathy Srokowski
AOXI0445	Evaluation of the attenuation degree of cold-adapted live attenuated SARS-CoV-2 vaccine candidate in K18-hACE2 transgenic mice	Jieun Park
AOXI0504	Predictive value of reactogenicity for anti-SARS-CoV-2 antibody response in mRNA-1273 recipients: a multicenter prospective cohort study	Min Joo Choi
AOXI0507	Six-month longitudinal immune kinetics after mRNA-1273 vaccination: correlation analysis of peak antibody response with long-term, cross-reactive humoral and cellular immunity	Min Joo Choi
AOXI0545	Household transmission of SARS-CoV-2: Effect of vaccination	Alexandra (Lexie) Mellis
AOXI0559	Comparative antibody persistence after natural COVID-19 infection or a primary course of 2 doses of either mRNA or inactivated COVID-19 vaccines	Wing Kwan Ng (Ken), Yiyang Guo
AOXI0562	Differential antibody response of 1 dose of either mRNA or inactivated COVID-19 vaccines after natural COVID-19 infection compared to 2 doses of vaccination in healthy population	Yiyang Guo
TRANSLATIONAL: Influenza - Improved seasonal vaccines		
AOXI0005	Molecular characterization of haemagglutinin genes of influenza B viruses circulating in Ghana during 2016 and 2017	Alhassa Mohammed Yakubu
AOXI0025	Comparability of antibody titers against seasonal influenza vaccine strains using cell- and egg derived target viruses in hemagglutination inhibition assays	Marten Heeringa
AOXI0041	Multiple Factors impact Antibody Responses to A(H3N2) viruses Following Influenza Vaccination	Min z Levine
AOXI0047	Influenza self-amplifying vaccines encoding influenza internal proteins raise robust both cellular immune responses	Yingxia Wen, Evan Rossignol
AOXI0060	Comparison of the Immunogenicity of Egg-Grown Inactivated Influenza Vaccine and Recombinant-Hemagglutinin Influenza Vaccine among Infrequently and Frequently Vaccinated Healthcare Personnel: A Randomized Open-Label Trial in Israel	Mark Thompson
AOXI0067	Investigating the influence of influenza vaccine formulation on original antigenic sin responses in a longitudinal cohort of children	Hannah Stacey
AOXI0074	Live Recombinant NDV vectored vaccine expressing the HA of H9N2 Avian influenza virus suppresses viral replications in chickens	Song JUHO Joo-Ho
AOXI0095	Production of cell-cultured seasonal influenza vaccine viruses with genetic stability and maintained antigenicity	Hitoshi Takahashi
AOXI0102	Long term durability of antigen-specific polyfunctional CD4 T-cell responses against vaccine-homologous and antigenically drifted viruses: Results of a Phase 3 Trial of a Recombinant Quadrivalent Hemagglutinin Saponin-adjuvanted Nanoparticle Influenza Vaccine in Older Adults	Vivek Shinde

POSTER SESSION II - Tuesday 27 September 2022

ABSTRACT	TITLE	PRESENTER
AOXI0114	Preclinical development of seasonal influenza mRNA vaccine candidates	Daniel Stadbauer
AOXI0117	Influenza QIV mRNA formulated in a LNP is highly immunogenic in the ferret model	Maryann Giel-Moloney
AOXI0123	Real-world relative effectiveness of MF59-adjuvanted influenza vaccine vs. high-dose or vs. standard dose influenza vaccines to prevent hospitalizations in older adults during the 2019-2020 U.S. influenza season	Mahrukh Imran
AOXI0124	Real-world relative effectiveness of cell-based quadrivalent influenza vaccine vs. egg-based quadrivalent influenza vaccine to prevent hospitalizations in adults 18-64 years of age during the 2019-2020 U.S. influenza season	Mahrukh Imran
AOXI0130	Antibody response to influenza A following sequential vaccination with egg-based, cell culture-based, and recombinant quadrivalent influenza vaccines among adults aged 18-64 years: a randomized open-label trial, 2018-19 and 2019-20	Jennifer King
AOXI0132	Humoral and cell-mediated responses to A(H3N2) component of cell culture-based and recombinant quadrivalent influenza vaccines compared to conventional egg-based quadrivalent influenza vaccines among healthcare personnel aged 18-64 years	Margarita Mishina
AOXI0135	COMPARISON OF SAFETY PROFILES OF FOUR MF59-ADJUVANTED CELL CULTURE-DERIVED MONOVALENT PANDEMIC VACCINES	Eve Versage
AOXI0160	The antigenic landscape of recent human influenza virus N2 neuraminidases circulating in 2009-2017	Joao Portela Catani
AOXI0174	The association of prior-year vaccination on antibody response to A(H3N2) with standard-dose, MF59-adjuvanted, high-dose, and recombinant-HA influenza vaccines in older adults.	Zhong Shuyi
AOXI0220	Results from the Enhanced Passive Safety Surveillance for the influenza vaccine Influvac Tetra in Germany during 2021/2022 vaccination season	Melanie Moller-Arendt
AOXI0224	Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Age and Seasonal Characteristics: An Updated Systematic Review and Meta-Analysis	Jason Lee
AOXI0234	Assay Harmonisation and Use of Biological Standards to Improve the Reproducibility of the Haemagglutination Inhibition Assay: A FLUCOP collaborative study	Othmar Engelhardt
AOXI0263	Influenza virus neuraminidase delivered as recombinant protein or mRNA is highly immunogenic in ferrets.	Guadalupe Cortes-Garcia
AOXI0274	Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain fusions	Nidhi Mittal
AOXI0325	Egg-adaptation pathway of human influenza H3N2 virus is contingent on natural evolution	Liang Weiwen
AOXI0355	USE OF THE NF-KB ACTIVATION ASSAY ENSURES INFLUENZA VACCINE SAFETY	Christine Wadey
AOXI0361	Recombinant HA protein vaccine fused with RNA interaction domain induce significant humoral and cellular immune response against influenza virus	Sohwa Kim
AOXI0433	Modification of HA glycosylation for the generation of efficacious vaccines against avian influenza viruses	Jong Hyeon Seok
AOXI0444	Inactivation of antigen-displayed baculovirus using natural products : a proof-of-concept for influenza vaccine	Yeh Eun Kim
AOXI0446	Durable seroprotective antibody responses after repeated trivalent seasonal influenza vaccination in healthcare workers	Mai-Chi Trieu
AOXI0466	FLUCOP collaborative study: assay harmonization for improving the reproducibility of the virus neutralization assay	Emanuele Montomoli, Claudia Maria Trumbetta
AOXI0481	Machine learning modeling of hemagglutinin antigenic relationships towards selection of broadly protective H3 antigens	Raul Gomila
AOXI0521	Human antibody response to trivalent split and polymer adjuvanted subunit influenza vaccines during one year after immunization	Maria Sergeeva
AOXI0539	Hemagglutination inhibition antibody titer is a partial mediator of seasonal and pandemic influenza vaccines	Wey Wen Lim
AOXI0573	Development of novel, recombinant seasonal Influenza vaccine	Chakshuusmathi Ghadiyaram
AOXI0630	Machine-Learning based selections of Different H3 Hemagglutinin Antigens show diverse breadth of immune response: A Randomized Controlled Trial of Recombinant Influenza Vaccine Formulations in Healthy Adult Subjects 18 to 30 Years of Age	Saranya Sridhar
AOXI0642	Egg adaptations and vaccine immunogenicity: beneficial effect of maintaining glycosylation while allowing other egg-adaptive changes	Annette Fox Marsh
TRANSLATIONAL: Influenza - Broadly protective/universal influenza virus vaccines		
AOXI0029	Influenza virus circulation, Brazil, 2010-2018.	Erika Rossetto
AOXI0062	A Computationally Optimized Broadly Reactive Hemagglutinin Elicits Neutralizing Antibodies Against Strains of Influenza B Viruses from Both Lineages	Michael Carlock
AOXI0108	HOW TO DRASTICALLY IMPROVE INFLUENZA PREVENTION? THE ADDITION OF A T-CELL COMPONENT TO INCREASE CURRENT VACCINE EFFICACY: PRECLINICAL AND EARLY CLINICAL RESULTS	Delphine Guyon-Gellin, Alexandre Escoffier, Alexandre Le Vert
AOXI0121	A Prospective Cohort Study on Pregnancy Outcomes in Women Immunized with Seasonal Quadrivalent Influenza Vaccine (QIV) During Pregnancy	Josephine (Jose) Van Boxmeer, Janine Oberye
AOXI0141	Can the M2 ectodomain (M2e) stabilize neuraminidase (NA) tetramers and broaden its immune protective potential?	Marlies Ballegeer
AOXI0159	Design, characterization, and immunogenic profile of Influenza HA stem nanoparticles	Sara Khaleeq

POSTER SESSION II - Tuesday 27 September 2022

ABSTRACT	TITLE	PRESENTER
AOXI0172	Immunogenicity and cross-protection of universal live-attenuated influenza vaccine candidates expressing multiple M2e epitopes in preclinical ferret study	Daria Mezhenskaia
AOXI0232	RESULTS OF A PHASE 2 STUDY WITH OVX836 SUGGEST EFFECTIVENESS IN PREVENTING INFLUENZA-LIKE ILLNESS AND CONFIRM GOOD SAFETY PROFILE	Delphine Guyon-Gellin, Alexandre Escoffier, Alexandre Le Vert
AOXI0314	Influenza hemagglutinin stem nanoparticle vaccine (H1ssF) induces cross-reactive neutralizing antibodies against group 1 influenza: a phase 1 trial in healthy adults	Amelia Hofstetter
AOXI0335	ITERATIVELY DESIGNED HEMAGGLUTININ BASED H5Nx ANTIGENS GENERATE A BROAD NEUTRALISING IMMUNE RESPONSE IN MICE	Sneha Vishwanath
AOXI0340	Matrix M adjuvanted H5N1 vaccine elicits broadly neutralizing antibodies and neuraminidase inhibiting antibodies in humans that correlate with in vivo protection	Fan Zhou
AOXI0343	Generation of an attenuated chimeric bat influenza A virus live vaccine prototype	Sebastian Giese
AOXI0357	Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants	Jeonghun Kim
AOXI0385	Immunogenicity and efficacy of a broadly reactive H1N1 Influenza vaccine in pigs	Pauline Van Diemen
AOXI0388	Characterization fo the human pre-existing COBRA HA-reactive antibody response following influenza vaccination.	Giuseppe Sautto
AOXI0398	Immunogenicity and Safety of High-Dose Versus Standard-Dose Influenza Vaccine in Adult Hematopoietic Stem Cell Transplant Recipients	Lora Thomas
AOXI0408	An ABCD Influenza virus pseudotype library: generating a globally accessible resource for immunogenicity studies of universal vaccines	Nigel Temperton
IMPLEMENTATION: Burden of Disease for Influenza and Dual Epidemics		
AOXI0303	Hospitalization reduction and excess deaths associated with the COVID-19 pandemic in Hong Kong, China, 2020	Hualei Xin
AOXI0483	Differences in seroprevalence between epicenter and non-epicenter areas of the COVID-19 outbreak in South Korea	Seung-Gyu Jang
IMPLEMENTATION: Pandemic Preparedness and Response		
AOXI0487	Knowledge, attitudes and practices towards COVID-19 among populations of Islamabad and Rawalpindi during lockdown: A cross-sectional survey	Nadia Nisar
IMPLEMENTATION: Surveillance for Influenza Including Joint Surveillance and Impact of COVID-19 on Other Respiratory Virus Diseases		
AOXI0287	Frailty, age and outcomes of hospitalized adults differ across waves of the COVID-19 pandemic; a report from the CIRN Serious Outcomes Surveillance (SOS) Network	Allison McGeer, Melissa Andrew
AOXI0632	SARS-CoV-2 VOCs monitoring using RT-PCR protocols by inference in Brazil	Paola Resende, Marilda Siqueira, Leonardo Saboia-Vahia
IMPLEMENTATION: Vaccine Effectiveness for COVID-19 and Implications for Influenza		
AOXI0091	Contributions of vaccination and infection to SARS-CoV-2 seroprevalence in a rural Wisconsin cohort from November 2020 to September 2021.	Josh Petrie
AOXI0118	Effect of Covid - 19 vaccination on the duration to stay at the hospital among patients with SARS-CoV 2 infection	Martin Herbas Ekart
AOXI0156	Intensity and trajectory of symptoms among people with SARS-CoV-2 infections	Carlos Grijalva
AOXI0209	The Regional COVID-19 Vaccine Effectiveness (VE) Studies in the Eastern Mediterranean Region (EMR)	Mehrnaz Kheirandish
AOXI0271	Effectiveness of whole virus COVID-19 vaccine at protecting health care personnel against SARS-CoV-2 infections in Lima, Peru	Carmen Arriola
AOXI0306	Vaccine effectiveness of 3rd mRNA-1273 dose against COVID-19 among agricultural workers in a prospective cohort in Guatemala	Eduardo Azziz-Baumgartner, Anna Chard, Chelsea Iwamoto
AOXI0309	Evaluating COVID-19 mRNA vaccine effectiveness in preventing asymptomatic and symptomatic SARS-CoV-2 infection in a prospective cohort of frontline workers in the United States, December 2020 - February 2022	Ashley Fowlkes
AOXI0339	The European Severe Acute Respiratory Infection Vaccine Effectiveness (Euro-SAVE) Network: a new network for evaluating the effectiveness of COVID-19 and Influenza vaccines in preventing severe illness in countries in the European Region of the World Health Organization	Mark Katz
AOXI0353	Vaccine effectiveness against hospitalisation with COVID-19 prior to and during Delta circulation in Europe in adults aged 30 yrs and over: I-MOVE-COVID-19 and ECDC hospital networks, January-December 2021	Angie Rose
AOXI0358	Adverse reactions to the BNT162b2 mRNA COVID-19 vaccine in healthy Japanese adults	Ayako Konishi
AOXI0365	A systematic review of immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation	Bingyi Yang
AOXI0368	Effectiveness of CoronaVac and BNT162b2 vaccine against SARS-CoV-2 Omicron infections in Hong Kong	Bingyi Yang
AOXI0492	COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan (FASCINATE study): implications for studies of influenza and other respiratory viruses	Takeshi Arashiro, Miyako Otsuka

POSTER SESSION II - Tuesday 27 September 2022

ABSTRACT	TITLE	PRESENTER
AOXI0505	Reported effectiveness of COVID-19 booster vaccines: a systematic review of early literature and implications for emerging vaccination policy	Josh Nealon
AOXI0542	COVID-19 Vaccine Effectiveness During Delta and Omicron Waves in a University Population	Julia Bennett
AOXI0544	Association of Previous Influenza Vaccination Practice and COVID-19 Vaccine Acceptance	Hau Chi So, Nicole Tsang Ngai Yung
IMPLEMENTATION: Vaccine Effectiveness for Influenza		
AOXI0016	Vaccine effectiveness against A(H3N2) viruses in the United States during 2021-22, US Flu VE Network	Jessie Chung
AOXI0023	Influenza vaccine effectiveness among adults 65 years of age and older: A systematic review of high dose inactivated, adjuvanted inactivated, and recombinant influenza vaccines	Lenee Blanton
AOXI0030	Influenza B vaccine effectiveness: exploring the impact of lineage-specific prior vaccination history	Maria Sundaram
AOXI0049	Use of heterologous antisera to determine influenza potency using the single radial diffusion assay	Christine Wadey
AOXI0070	Inactivated influenza vaccination did not reduce influenza viral load at diagnosis among young Japanese children during the 2013/2014 through 2017/2018 influenza seasons	Emiko Mukai
AOXI0096	Real-World Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children During Multiple Seasons: 2016-2021	Allyn Bandell
AOXI0097	Evaluation of US expert opinion on the association between influenza vaccine effectiveness (VE) and egg-based manufacturing technology	Victor Huber
AOXI0100	NA antigenic drift between H3N2 clades may have contributed to decreased vaccine effectiveness for the A/New Caledonia/71/2014 LAIV during the 2017-18 season.	David Burbidge
AOXI0115	Efficacy and effectiveness of high-dose influenza vaccine compared with standard-dose influenza vaccine among older adults: A systematic review and meta-analysis	Jill Ferdinands
AOXI0153	Effectiveness of influenza vaccines in preventing infections in households: a case-ascertained study	Carlos Grijalva
AOXI0242	Influenza Vaccine Effectiveness among Hospitalized Adults Age 50 or Greater with ARI and among Hospitalized Adults 18 Years or Greater with Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF) Exacerbations	Evan Anderson
AOXI0244	Relative Vaccine Effectiveness of the MF59-Adjuvanted Trivalent Seasonal Influenza Vaccine Compared to High-Dose Trivalent Seasonal Influenza Vaccine Among Adults 65 Years of Age or Older, a Systematic Literature Review and Meta-Analysis	Ian McGovern
AOXI0264	Evaluating the potential for a non-pharmacological adjuvant to enhance influenza vaccine effectiveness in older adults: A three-arm randomised controlled trial	Jonathan Van-Tam, Sophie Carlisle
AOXI0270	Influenza Vaccine Effectiveness in Patients Hospitalized with Severe Acute Respiratory Infection in Lithuania During the 2019/2020 Influenza Season	Roberta Vaikutyte
AOXI0295	Cost-effectiveness of seasonal influenza vaccination in WHO defined- high-risk population in Bangladesh	Md. Zakuil Hassan
AOXI0410	THE IMPACT OF INFLUENZA VACCINE EFFECTIVENESS ON U.S. HOSPITAL SYSTEM RESOURCES WITHIN AN INFLUENZA AND COVID-19 CO-CIRCULATION SCENARIO.	Joaquin Mould
AOXI0416	Comparison of live attenuated and inactivated influenza vaccine induced hemagglutinin and neuraminidase inhibiting antibody responses in children	Sarah Lartey Jalloh
AOXI0438	Influenza vaccine immunogenicity in hemodialysis patients	Anna-Polina Shurygina
AOXI0459	Seasonal influenza vaccination associated with attenuated illness among hospitalized patients in four South American countries	Annette Regan
AOXI0535	Vaccination history impacts hemagglutinin and neuraminidase antibody responses following influenza vaccination	Sanja Trifkovic
AOXI0537	Repeated influenza vaccination effects on vaccine effectiveness in vaccinated individuals in the United Kingdom	Wey Wen Lim
AOXI0563	Consistency of Comparative Side Effect Profiles of Inactivated Influenza Vaccine (IIV) and Live-Attenuated Influenza Vaccine (LAIV) among School Children in Hong Kong: A three-year longitudinal study	Yawei Wang
AOXI0571	Impact of prior vaccination on breadth of antibody response among healthcare workers after influenza vaccination	Annette Fox Marsh
AOXI0588	Selecting high-yield vaccine candidates directly from epidemic influenza viruses using machine learning	Xiu-Feng (Henry) Wan
AOXI0656	Influenza vaccine responses to A(H1N1)pdm09 antigens in 2020 and 2021 among repeatedly vaccinated healthcare workers	Annette Fox Marsh
BASIC: Influenza - Adaptive immune response to infection		
AOXI0040	Distinctive Antibody Landscapes Resulting from Influenza Infection and Vaccination	Zhunan Li
AOXI0201	Timing of Influenza Virus Exposure in Early Childhood among Nicaraguan Children	Aaron Frutos
AOXI0249	Versatile virus microneutralization assay for high-throughput assessment of influenza antibodies	Rebecca Gillespie
AOXI0273	Mucosal Antibody Responses Against Influenza Antigens do not Correlate with Serum Antibody Responses in Healthy Volunteers undergoing Influenza Viral Challenge	Luca Giurgea

POSTER SESSION II - Tuesday 27 September 2022

ABSTRACT	TITLE	PRESENTER
AOXI0288	Impact of dietary calories restriction on protective immunity to influenza infection	Shivaprakash Gangappa
AOXI0382	Identification and Characterization of Human Memory B Cell Receptors Targeting Influenza Virus Hemagglutinin Proteins	Jason Wilson
AOXI0409	Characterization of three human monoclonal influenza NP antibodies	Walter Harrington
AOXI0423	Establishment of a baculovirus platform for the study of neuraminidase inhibitory antibodies	Yulia Desheva
AOXI0476	Dissecting heterogenous polyclonal antibody responses to Influenza vaccination using cryoEMPEM	James Ferguson
AOXI0525	Influenza virus-derived epitopes induce CD8 T cell recognition across different HLA allotypes	Hazem Hamza Ewess
AOXI0526	Structural and dynamic characterization of broadly neutralizing anchor epitope binding antibodies	Monica Fernandez-Quintero
AOXI0550	Fourfold rises in antibody titre to age-appropriate historical strains of influenza B suggest higher rates of infection than do homologous strains	Kin ON Kwok
AOXI0638	Antibody Inhibition of Influenza A Virus Assembly	Yuanyuan He
AOXI0650	Mapping the Polyclonal IgG Response To Hemagglutinin After Acute H1N1 or H3N2 Influenza Virus Infections	Andre Leon
BASIC: Influenza - Innate immune response to infection		
AOXI0003	Development and characterization of an Aerodynamic system for pulmonary delivery of Influenza vaccine	Saurabh Bhargava
AOXI0138	Development of Bipolymer based Novel Nanoparticles in Microsphere System as Vaccine Adjuvant	Prakash Gosain
AOXI0140	Previous obesity increases the severity of influenza virus infection via the induction of innate immune training	Ellesandra Noye
AOXI0180	Modulation of the host immune response by an influenza A virus with cytoplasm-only non-structural protein 1	Chun Yee Tam
AOXI0283	Antigenic map of the hemagglutinin of influenza A virus of the H9 subtype	Daniel R Perez, C. Joaquin Caceres
AOXI0596	Multidisciplinary INvesTIGATION of Transmission to Ease influenza (MITIGATE FLU)	Linsey Marr
AOXI0598	Experiments to Evaluate Respirable Aerosols Produced during Different Poultry Defeathering Methods	Nadia Rimi
BASIC: SARS-CoV-2: novel treatment and prevention strategies		
AOXI0002	Replication of SARS-CoV-2 in adipose tissue determines organ and systemic lipid metabolism in hamsters and humans	Martin Zickler
AOXI0103	SARS-CoV2 preS dTM-AS03 vaccine boosters induce broad and persistent cross-neutralizing responses against SARS-CoV-2 variants of concern in primed non-human primates	Valerie Lecouturier
AOXI0104	A bivalent subunit SARS-CoV2 preS dTM (D614 and B.1.351) with AS03-adjuvant vaccine induces broad and long-term neutralizing responses against SARS-CoV-2 variants in naïve non-human primates	Valerie Lecouturier
AOXI0134	Pharmacokinetic parameters and pharmacodynamics of ensitrelvir (S-217622) in animal models of SARS-CoV-2 infection	Haruaki Nobori
AOXI0136	The antiviral activity of ensitrelvir (S-217622) against various SARS-CoV-2 strains	Masaaki (Masa) Nakashima
AOXI0168	Ensitrelvir (S-217622), a small molecule inhibitor of 3C-like protease of SARS-CoV-2, reduced mortality, improved virus-induced lung inflammation and respiratory dysfunction in animal models.	Keita Fukao
AOXI0204	Identification of COVID-19 prognostic signature and therapeutic agent through OMICs Meta-analysis and validation in a patient cohort.	Shashank Tripathi
AOXI0233	Validation of a Predictive Model to Correlate Neutralization Titers and Efficacy for the Prevention of COVID-19	Pete C. Schmidt
AOXI0255	Clinical use of molnupiravir and the combination with sotrovimab for SARS-CoV-2 infected (COVID-19) patients in a tertiary hospital of Japan	Masafumi Seki
AOXI0297	Functional analysis of polymeric monoclonal anti-SARS-CoV-2 IgA antibodies	Akira Ueno
AOXI0312	Antibody responses after two-doses of inactivated vaccine followed by a booster dose of either viral-vector or mRNA COVID-19 vaccine in healthcare workers in Thailand	Kriengkrai Prasert
AOXI0371	Intranasal vaccine with ODN2006 as an adjuvant protects against viral infection with reducing the potential risk of lung eosinophilic immunopathology.	Takuya Hemmi
AOXI0447	Surface expression of SARS-Cov-2 epitopes in Enterococcus L3 to develop live peroral vaccine	Yulia Desheva (Iuliia)
AOXI0449	Neutralization of SARS-CoV-2 by antibodies elicited after COVID-19 mRNA vaccination varies depending on immunization schedule and variants of concern/interest	Han Di
AOXI0451	SAB-185 protects human ACE2 transgenic Syrian hamsters against multiple SARS CoV-2 variants including Omicron	Thomas Luke
AOXI0467	Self-amplifying Replicon RNA vaccine induces broad antibody responses in pre-immune nonhuman primates and durable protection from SARS-CoV-2 even after neutralizing antibodies wane to undetectable levels	Deborah Fuller
AOXI0554	Multi epitopes vaccine & a novel therapy against SARS-CoV-2	Shah Md. Shahik

POSTER SESSION II - Tuesday 27 September 2022

ABSTRACT	TITLE	PRESENTER
AOXI0565	Evaluation of Major Components of Green Plants, as Potential Therapeutics for SARS-CoV-2 variants	Eun-Ha Kim
AOXI0625	SARS-CoV-2 Ancestral and Variant of Concern Breakthrough infections boost both cross-reactive cellular and humoral immune responses in mRNA-vaccinated Hamsters.	Michael Schotsaert
AOXI0660	Functional screening of SARS-CoV-2 reveals novel antiviral targets	Laura Martin-Sancho
AOXI0661	Intranasal delivery of recombinant subunit vaccine formulated with novel mucosal adjuvant protects mice and ferrets against SARS-CoV-2 challenge	Jeon-Hyun Jeong
AOXI0205	Absence of rapid T cell control corresponds with delayed viral clearance in hospitalised COVID-19 patients	Jutte de Vries
BASIC: Zoonotic influenza		
AOXI0328	Live Recombinant NDV vectored vaccine expressing the HA of H9N2 Avian influenza virus suppresses viral replications in chickens.	Song JUHO Joo-Ho
AOXI0345	Live Recombinant NDV vectored vaccine expressing the HA of H9N2 Avian influenza virus suppresses viral replications in chickens.	Song JUHO Joo-Ho
AOXI0671	Effective use of influenza surveillance and response capacities for Covid-19 utilizing Pandemic Influenza Preparedness Program: an experience from Jordan	Lora Alsawalha